Litcius/Paper detail

miR-486-5p: A Prognostic Biomarker for Chronic Myeloid Leukemia

Anuupama Suchiita, Sameer Ahmad Guru, Prasant Yadav, Mirza Masroor, Amit Samadhiya, Namrata Bhutani, Naresh Gupta, Richa Gupta, Alpana Saxena

2021ACS Omega26 citationsDOIOpen Access PDF

Abstract

. To the best of our knowledge, this is the first report of alterations in the miR-486-5p expression in peripheral blood leucocytes of CML patients. Our observations support a tumor suppressor role of miR-486-5p in CML. The downregulation of the miR-486-5p expression may be critically important in the disease progression of CML patients. The upregulation of the miR-486-5p expression in post-imatinib exposure K562 cells and CML patients after 12 months of imatinib treatment suggests an onco-suppressor effector role of miR-486-5p in the BCR-ABL downstream signaling pathway. miR-486-5p can be explored as a novel biomarker for the early detection of CML.

Topics & Concepts

Myeloid leukemiaImatinibMedicineBiomarkerReal-time polymerase chain reactionImatinib mesylateInternal medicineGastroenterologymicroRNADownregulation and upregulationK562 cellsLeukemiaOncologyImmunologyBiologyGeneBiochemistryChronic Myeloid Leukemia TreatmentsPI3K/AKT/mTOR signaling in cancerT-cell and Retrovirus Studies